Cyllene Therapeutics Secures US FDA RMAT Designation for EG110A in Neurogenic Detrusor Overactivity

Shots: The US FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to EG110A to treat neurogenic detrusor overactivity (NDO) with urinary incontinence  The designation was based on the initial P-Ib/IIa trial data, ongoing in the US, in pts with NDO associated with spinal cord injury, with interim results to be presented at the ICS Annual Conference in Oct 2026. Also, a P-IIb/III trial for NDO is planned in 2027 EG110A, developed from Cyllene Tx’s HERMES platform, is a non-replicating HSV-1 vector designed to selectively silence CGRP+ (type C) sensory neurons driving bladder overactivity while preserving normal bladder function Ref: Cyllene |  Image: Cyllene |  Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post Cyllene Therapeutics Secures US FDA RMAT Designation for EG110A in Neurogenic Detrusor Overactivity appeared first on PharmaShots.